Review on fungal enzyme inhibitors – potential drug targets to manage human fungal infections

Invasive fungal infections caused by opportunistic fungal pathogens have been emerging as a global problem of great concern as they are associated with increased morbidity and mortality. Despite this, there are very limited drugs of choice to treat fungal infections. The continuous usage of these drugs is associated with resistance development and thus this is another area of concern. Fungal enzymes represent one of the most important and potential targets for drug development, as they are essential for their growth and establishment in the host. In this review, we have discussed the well established and currently available enzyme inhibitors as therapeutic choices to treat fungal infections as well as those enzyme inhibitors that have been identified as suitable drug candidates to manage fungal infections. Thus, the study of fungal biosynthetic enzymes and their inhibitors could potentially show a promising way of drug development for emerging and re-emerging fungal infections of humans.

[1]  C. Supuran,et al.  Carbonic anhydrase inhibitors: inhibition of the β-class enzyme from the pathogenic yeast Candida glabrata with sulfonamides, sulfamates and sulfamides. , 2013, Bioorganic & medicinal chemistry letters.

[2]  Shengzheng Wang,et al.  Erg11 mutations associated with azole resistance in clinical isolates of Candida albicans. , 2013, FEMS yeast research.

[3]  M. Rinaldi,et al.  In Vitro Antifungal Activity of Nikkomycin Z in Combination with Fluconazole or Itraconazole , 1999, Antimicrobial Agents and Chemotherapy.

[4]  J. Cleary,et al.  Effect of Candida glabrata FKS1 and FKS2 Mutations on Echinocandin Sensitivity and Kinetics of 1,3-β-d-Glucan Synthase: Implication for the Existing Susceptibility Breakpoint , 2009, Antimicrobial Agents and Chemotherapy.

[5]  D. Horn,et al.  Factors related to survival and treatment success in invasive candidiasis or candidemia: a pooled analysis of two large, prospective, micafungin trials , 2010, European Journal of Clinical Microbiology & Infectious Diseases.

[6]  Y. Koltin,et al.  The search for new triazole antifungal agents. , 1997, Current opinion in chemical biology.

[7]  M. Martín,et al.  The use of fluconazole and itraconazole in the treatment of Candida albicans infections: a review. , 1999, The Journal of antimicrobial chemotherapy.

[8]  D. Stevens,et al.  Paradoxical Effect of Caspofungin: Reduced Activity against Candida albicans at High Drug Concentrations , 2004, Antimicrobial Agents and Chemotherapy.

[9]  Duncan W. Wilson,et al.  Candida albicans pathogenicity mechanisms , 2013, Virulence.

[10]  C. Supuran Structure-based drug discovery of carbonic anhydrase inhibitors , 2012, Journal of enzyme inhibition and medicinal chemistry.

[11]  L. Harrison,et al.  Declining Incidence of Candidemia and the Shifting Epidemiology of Candida Resistance in Two US Metropolitan Areas, 2008–2013: Results from Population-Based Surveillance , 2015, PloS one.

[12]  T. C. White,et al.  Azole Drug Import into the Pathogenic Fungus Aspergillus fumigatus , 2015, Antimicrobial Agents and Chemotherapy.

[13]  P. O'Hara,et al.  Molecular cloning, cDNA sequence, and bacterial expression of human glutamine:fructose-6-phosphate amidotransferase. , 1992, The Journal of biological chemistry.

[14]  C. Supuran,et al.  Drug Design of Zinc-Enzyme Inhibitors , 2009 .

[15]  M. Arisawa,et al.  A new methionine antagonist that has antifungal activity: mode of action. , 1994, The Journal of antibiotics.

[16]  T. Osaki,et al.  Lactoferrin Peptide Increases the Survival ofCandida albicans- Inoculated Mice by Upregulating Neutrophil and Macrophage Functions, Especially in Combination with Amphotericin B and Granulocyte-Macrophage Colony-Stimulating Factor , 2001, Infection and Immunity.

[17]  S. Kelly,et al.  Azole Resistance by Loss of Function of the Sterol Δ5,6-Desaturase Gene (ERG3) in Candida albicans Does Not Necessarily Decrease Virulence , 2012, Antimicrobial Agents and Chemotherapy.

[18]  B. Posteraro,et al.  Comparative Effects of Micafungin, Caspofungin, and Anidulafungin against a Difficult-To-Treat Fungal Opportunistic Pathogen, Candida glabrata , 2011, Antimicrobial Agents and Chemotherapy.

[19]  S. Pöggeler,et al.  Carbonic anhydrases in fungi. , 2010, Microbiology.

[20]  D. Perlin Echinocandin Resistance, Susceptibility Testing and Prophylaxis: Implications for Patient Management , 2014, Drugs.

[21]  E. Borowski,et al.  Glucosamine-6-phosphate synthase, a novel target for antifungal agents. Molecular modelling studies in drug design. , 2005, Acta biochimica Polonica.

[22]  Martin Pouliot,et al.  Pan Assay Interference Compounds (PAINS) and Other Promiscuous Compounds in Antifungal Research. , 2016, Journal of medicinal chemistry.

[23]  C. Vigen,et al.  Reduction of catheter-related bloodstream infections through the use of a central venous line bundle: epidemiologic and economic consequences. , 2011, American journal of infection control.

[24]  A. Balaban,et al.  Carbonic anhydrase inhibitors. Synthesis of 2,4,6-trimethylpyridinium derivatives of 2-(hydrazinocarbonyl)-3-aryl-1H-indole-5-sulfonamides acting as potent inhibitors of the tumor-associated isoform IX and XII. , 2009, Bioorganic & medicinal chemistry letters.

[25]  K. Isono,et al.  Studies on polyoxins, antifungal antibiotics. 13. The structure of polyoxins. , 1969, Journal of the American Chemical Society.

[26]  R. Schwartz,et al.  Discovery of Novel Antifungal (1,3)-β-d-Glucan Synthase Inhibitors , 2000, Antimicrobial Agents and Chemotherapy.

[27]  B. Reinhold,et al.  Architecture of the Yeast Cell Wall , 1997, The Journal of Biological Chemistry.

[28]  Keshia M. Pollack,et al.  The publics' understanding of daily caloric recommendations and their perceptions of calorie posting in chain restaurants , 2010, BMC public health.

[29]  Alistair J. P. Brown,et al.  Immune Recognition of Candida albicans β-glucan by Dectin-1 , 2007 .

[30]  D. Perlin,et al.  Correlating Echinocandin MIC and Kinetic Inhibition of fks1 Mutant Glucan Synthases for Candida albicans: Implications for Interpretive Breakpoints , 2008, Antimicrobial Agents and Chemotherapy.

[31]  P. Smith,et al.  Antifungal Therapy and Outcomes in Infants With Invasive Candida Infections , 2012, The Pediatric infectious disease journal.

[32]  N. Gow,et al.  Stimulation of Chitin Synthesis Rescues Candida albicans from Echinocandins , 2008, PLoS pathogens.

[33]  D. Andes,et al.  Pharmacodynamic Target Evaluation of a Novel Oral Glucan Synthase Inhibitor, SCY-078 (MK-3118), Using an In Vivo Murine Invasive Candidiasis Model , 2014, Antimicrobial Agents and Chemotherapy.

[34]  Z. Hashemizadeh,et al.  Opportunistic invasive fungal infections: diagnosis & clinical management , 2014, The Indian journal of medical research.

[35]  D. Stevens,et al.  Antifungal drug resistance. , 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[36]  Russell E. Lewis,et al.  Attenuation of the Activity of Caspofungin at High Concentrations against Candida albicans: Possible Role of Cell Wall Integrity and Calcineurin Pathways , 2005, Antimicrobial Agents and Chemotherapy.

[37]  K. Hellingwerf,et al.  Dynamics of cell wall structure in Saccharomyces cerevisiae. , 2002, FEMS microbiology reviews.

[38]  S. Levick,et al.  Community Composition and Abundance of Bacterial, Archaeal and Nitrifying Populations in Savanna Soils on Contrasting Bedrock Material in Kruger National Park, South Africa , 2016, Front. Microbiol..

[39]  Zhenyu Zhu,et al.  Enhancement of the antibiofilm activity of amphotericin B by polyamine biosynthesis inhibitors. , 2015, International journal of antimicrobial agents.

[40]  M. Stolarska,et al.  Synthesis, anticandidal activity of N(3)-(4-methoxyfumaroyl)-(S)-2,3-diaminopropanoic amide derivatives--novel inhibitors of glucosamine-6-phosphate synthase. , 2015, European journal of medicinal chemistry.

[41]  P. L. McCormack Isavuconazonium: First Global Approval , 2015, Drugs.

[42]  Purification and characterization of a cytochrome P450 isozyme catalyzing lanosterol 14α-demethylation (P45014DM) in hamster liver , 1995, Lipids.

[43]  E. Shuman,et al.  Epidemiology of central nervous system infection. , 2012, Neuroimaging clinics of North America.

[44]  Joseph Heitman,et al.  Synergistic Antifungal Activities of Bafilomycin A1, Fluconazole, and the Pneumocandin MK-0991/Caspofungin Acetate (L-743,873) with Calcineurin Inhibitors FK506 and L-685,818 against Cryptococcus neoformans , 2000, Antimicrobial Agents and Chemotherapy.

[45]  F. Botterel,et al.  Contribution of (1,3)-Beta-d-Glucan to Diagnosis of Invasive Candidiasis after Liver Transplantation , 2014, Journal of Clinical Microbiology.

[46]  D. Loebenberg,et al.  Three-Dimensional Models of Wild-Type and Mutated Forms of Cytochrome P450 14α-Sterol Demethylases from Aspergillus fumigatus and Candida albicans Provide Insights into Posaconazole Binding , 2004, Antimicrobial Agents and Chemotherapy.

[47]  R. Tovar,et al.  Meningitis due to Cryptococcus neoformans: treatment with posaconazole. , 2012, Current HIV research.

[48]  J. Perfect,et al.  Practice guidelines for the management of cryptococcal disease. Infectious Diseases Society of America. , 2000, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[49]  C. Supuran,et al.  Drug design of Zinc-enzyme inhibitors: functional, structural and disease applications , 2009 .

[50]  C. Steegborn,et al.  CO2 Acts as a Signalling Molecule in Populations of the Fungal Pathogen Candida albicans , 2010, PLoS pathogens.

[51]  Suresh Kumar,et al.  In-vitro antimicrobial screening and molecular docking studies of synthesized 2-chloro-N-(4-phenylthiazol-2-yl)acetamide derivatives , 2015 .

[52]  F. Barchiesi,et al.  In-vitro interaction of terbinafine with amphotericin B, fluconazole and itraconazole against clinical isolates of Candida albicans. , 1998, The Journal of antimicrobial chemotherapy.

[53]  M. Arendrup,et al.  Acquired antifungal drug resistance in Aspergillus fumigatus: epidemiology and detection. , 2011, Medical mycology.

[54]  J. Perfect,et al.  Use of Antifungal Combination Therapy: Agents, Order, and Timing , 2010, Current fungal infection reports.

[55]  S. Alper,et al.  Inhibition of Ca(2+)-dependent K+ transport and cell dehydration in sickle erythrocytes by clotrimazole and other imidazole derivatives. , 1993, The Journal of clinical investigation.

[56]  S. Silverman,et al.  The function of chitin synthases 2 and 3 in the Saccharomyces cerevisiae cell cycle , 1991, The Journal of cell biology.

[57]  Sergey V. Balashov,et al.  Assessing Resistance to the Echinocandin Antifungal Drug Caspofungin in Candida albicans by Profiling Mutations in FKS1 , 2006, Antimicrobial Agents and Chemotherapy.

[58]  M. Pfaller,et al.  Effects of cilofungin (LY121019) on carbohydrate and sterol composition ofCandida albicans , 1989, European Journal of Clinical Microbiology and Infectious Diseases.

[59]  G. Gece Drugs: A review of promising novel corrosion inhibitors , 2011 .

[60]  N. Greer Voriconazole: The Newest Triazole Antifungal Agent , 2003, Proceedings.

[61]  R. Jedrzejczak,et al.  Amide and ester derivatives of N3-(4-methoxyfumaroyl)-(S)-2,3-diaminopropanoic acid: the selective inhibitor of glucosamine-6-phosphate synthase. , 2001, Bioorganic & medicinal chemistry.

[62]  R. Cannon,et al.  Overexpression of Candida albicans CDR1, CDR2, or MDR1 Does Not Produce Significant Changes in Echinocandin Susceptibility , 2006, Antimicrobial Agents and Chemotherapy.

[63]  John R Perfect,et al.  Resistance to Antifungal Agents: Mechanisms and Clinical Impact , 2008 .

[64]  Ivone M. Martins,et al.  Differential Activities of Three Families of Specific β(1,3)Glucan Synthase Inhibitors in Wild-type and Resistant Strains of Fission Yeast* , 2010, The Journal of Biological Chemistry.

[65]  J. Heitman,et al.  Carbonic Anhydrase and CO2 Sensing during Cryptococcus neoformans Growth, Differentiation, and Virulence , 2005, Current Biology.

[66]  K. Kakiki,et al.  STUDIES ON THE MODE OF ACTION OF POLYOXINS. VI , 1974 .

[67]  Miguel C. Teixeira,et al.  Candida glabrata Drug:H+ Antiporter CgQdr2 Confers Imidazole Drug Resistance, Being Activated by Transcription Factor CgPdr1 , 2013, Antimicrobial Agents and Chemotherapy.

[68]  S. A. Parent,et al.  Specific Substitutions in the Echinocandin Target Fks1p Account for Reduced Susceptibility of Rare Laboratory and Clinical Candida sp. Isolates , 2005, Antimicrobial Agents and Chemotherapy.

[69]  Kana Matsumoto,et al.  Chronic invasive sinus and intracerebral aspergillosis controlled by combination therapy with micafungin and a daily dose of 400 mg itraconazole oral solution. , 2015, Journal of infection and chemotherapy : official journal of the Japan Society of Chemotherapy.

[70]  M. Pfaller,et al.  Antifungal drug resistance: mechanisms, epidemiology, and consequences for treatment. , 2012, The American journal of medicine.

[71]  P. Klein,et al.  Leucine oxidation changes rapidly after dietary protein intake is altered in adult women but lysine flux is unchanged as is lysine incorporation into VLDL-apolipoprotein B-100. , 1994, The Journal of nutrition.

[72]  Alistair J. P. Brown,et al.  The PKC, HOG and Ca2+ signalling pathways co‐ordinately regulate chitin synthesis in Candida albicans , 2007, Molecular microbiology.

[73]  D. Kontoyiannis,et al.  Caspofungin-Resistant Candida tropicalis Strains Causing Breakthrough Fungemia in Patients at High Risk for Hematologic Malignancies , 2008, Antimicrobial Agents and Chemotherapy.

[74]  J. Smith,et al.  In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872) , 1997, Antimicrobial agents and chemotherapy.

[75]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of the fungal beta-carbonic anhydrases from Candida albicans and Cryptococcus neoformans with boronic acids. , 2009, Bioorganic & medicinal chemistry letters.

[76]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition and homology modeling studies of the fungal beta-carbonic anhydrase from Candida albicans with sulfonamides. , 2009, Bioorganic & medicinal chemistry.

[77]  P. Gopal,et al.  Evidence for a glycosidic linkage between chitin and glucan in the cell wall of Candida albicans. , 1988, Journal of general microbiology.

[78]  C. Supuran,et al.  In-vitro antibacterial, antifungal and cytotoxic properties of sulfonamide—derived Schiff's bases and their metal complexes , 2005, Journal of enzyme inhibition and medicinal chemistry.

[79]  S. Kelly,et al.  Itraconazole resistance in Aspergillus fumigatus , 1997, Antimicrobial agents and chemotherapy.

[80]  C. Supuran,et al.  Carbonic anhydrase inhibitors. Inhibition of the β-class enzymes from the fungal pathogens Candida albicans and Cryptococcus neoformans with branched aliphatic/aromatic carboxylates and their derivatives. , 2011, Bioorganic & medicinal chemistry letters.

[81]  E. Borowski,et al.  Antihistoplasmal in vitro and in vivo effect of Lys-Nva-FMDP. , 1998, Medical mycology.

[82]  N. Gow,et al.  Fungal echinocandin resistance , 2010, Fungal genetics and biology : FG & B.

[83]  T. Raman,et al.  Magnesium Ion Acts as a Signal for Capsule Induction in Cryptococcus neoformans , 2016, Front. Microbiol..

[84]  R. Andruszkiewicz,et al.  Antifungal activity of thionated analogues of Nva-FMDP and Lys-Nva-FMDP. , 2009, Polish journal of microbiology.

[85]  J. Donnelly Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a ways to go. , 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[86]  B. Posteraro,et al.  Antifungal drug resistance among Candida species: mechanisms and clinical impact , 2015, Mycoses.

[87]  W. Sly,et al.  Structure, function and applications of carbonic anhydrase isozymes. , 2013, Bioorganic & medicinal chemistry.

[88]  S. Jaffar,et al.  Short course amphotericin B with high dose fluconazole for HIV-associated cryptococcal meningitis. , 2012, The Journal of infection.

[89]  D. Sheehan,et al.  Current and Emerging Azole Antifungal Agents , 1999, Clinical Microbiology Reviews.

[90]  Cynthia T. Nguyen,et al.  Role of New Antifungal Agents in the Treatment of Invasive Fungal Infections in Transplant Recipients: Isavuconazole and New Posaconazole Formulations , 2015, Journal of fungi.

[91]  A. Barnes,et al.  Non-albicans Candida spp. causing fungaemia: pathogenicity and antifungal resistance. , 2002, The Journal of hospital infection.

[92]  Gerard D. Wright,et al.  Identification and Characterization of New Inhibitors of Fungal Homoserine Kinase , 2011, Chembiochem : a European journal of chemical biology.

[93]  R. Kaneno,et al.  Paracoccidioides brasiliensis Interferes on Dendritic Cells Maturation by Inhibiting PGE2 Production , 2015, PloS one.

[94]  D. Perlin Mechanisms of echinocandin antifungal drug resistance , 2015, Annals of the New York Academy of Sciences.

[95]  P. Carver,et al.  Comparison of echinocandin antifungals , 2007, Therapeutics and clinical risk management.

[96]  F. Meunier,et al.  In-vitro activity of cilofungin (LY121019) in comparison with amphotericin B. , 1989, Journal of Antimicrobial Chemotherapy.

[97]  I. Gabriel,et al.  Inhibitors of amino acids biosynthesis as antifungal agents , 2014, Amino Acids.

[98]  K. Hellingwerf,et al.  Molecular organization of the cell wall of Candida albicans. , 2001, Medical mycology.

[99]  Alan S. Perelson,et al.  High Multiplicity Infection by HIV-1 in Men Who Have Sex with Men , 2010, PLoS pathogens.

[100]  Yanxia Shi,et al.  Design, Synthesis and Bioactivity of Novel Glycosylthiadiazole Derivatives , 2014, Molecules.

[101]  A. Velegraki,et al.  Saccharomyces boulardii fungaemia in an intensive care unit patient treated with caspofungin , 2008, Critical care.

[102]  A. Onderdonk,et al.  Effect of Candida albicans Infection and Clotrimazole Treatment on Vaginal Microflora In Vitro , 1995, Obstetrics and gynecology.

[103]  D. Falci,et al.  Profile of isavuconazole and its potential in the treatment of severe invasive fungal infections , 2013, Infection and drug resistance.

[104]  K. Kaila,et al.  Polyamines inhibit carbonic anhydrases by anchoring to the zinc-coordinated water molecule. , 2010, Journal of medicinal chemistry.

[105]  C. Clancy,et al.  Paradoxical Effect of Caspofungin against Candida Bloodstream Isolates Is Mediated by Multiple Pathways but Eliminated in Human Serum , 2011, Antimicrobial Agents and Chemotherapy.

[106]  J. Lopez-Ribot,et al.  In Vitro Activity of Caspofungin (MK-0991) against Candida albicans Clinical Isolates Displaying Different Mechanisms of Azole Resistance , 2002, Journal of Clinical Microbiology.

[107]  K. Garey,et al.  Echinocandin Resistance in Candida Species: Mechanisms of Reduced Susceptibility and Therapeutic Approaches , 2012, The Annals of pharmacotherapy.

[108]  P. Cos,et al.  Artemisinins, New Miconazole Potentiators Resulting in Increased Activity against Candida albicans Biofilms , 2014, Antimicrobial Agents and Chemotherapy.

[109]  P. Williamson,et al.  Role of Homoserine Transacetylase as a New Target for Antifungal Agents , 2007, Antimicrobial Agents and Chemotherapy.

[110]  W. Melchers,et al.  Failure of Posaconazole Therapy in a Renal Transplant Patient with Invasive Aspergillosis Due to Aspergillus fumigatus with Attenuated Susceptibility to Posaconazole , 2011, Antimicrobial Agents and Chemotherapy.

[111]  L. Cowen,et al.  Regulatory Circuitry Governing Fungal Development, Drug Resistance, and Disease , 2011, Microbiology and Molecular Reviews.

[112]  Jaqueline Moisés Tobal,et al.  Role of carbonic anhydrases in pathogenic micro-organisms: a focus on Aspergillus fumigatus. , 2014, Journal of medical microbiology.

[113]  S. Milewski Glucosamine-6-phosphate synthase--the multi-facets enzyme. , 2002, Biochimica et biophysica acta.

[114]  Claudiu T. Supuran,et al.  Carbonic anhydrases: novel therapeutic applications for inhibitors and activators , 2008, Nature Reviews Drug Discovery.

[115]  J. Mccusker,et al.  Cryptococcus neoformans Ilv2p confers resistance to sulfometuron methyl and is required for survival at 37 °C and in vivo , 2004 .

[116]  R. J. Herr,et al.  Discovery of a Novel Class of Orally Active Antifungal β-1,3-d-Glucan Synthase Inhibitors , 2011, Antimicrobial Agents and Chemotherapy.

[117]  L. Mutter,et al.  Efinaconazole: Developmental and reproductive toxicity potential of a novel antifungal azole. , 2015, Reproductive toxicology.

[118]  Y. Barenholz,et al.  Efficacy Evaluation of a Novel Submicron Miconazole Emulsion in a Murine Cryptococcosis Model , 1995, Pharmaceutical Research.

[119]  P. Robbins,et al.  Architecture of the Yeast Cell Wall , 1995, The Journal of Biological Chemistry.

[120]  A. Armaganidis,et al.  Invasive Fungal Infections in the ICU: How to Approach, How to Treat , 2014, Molecules.

[121]  Toru Nakai,et al.  Synthesis and antifungal activity of ASP9726, a novel echinocandin with potent Aspergillus hyphal growth inhibition. , 2014, Bioorganic & medicinal chemistry letters.

[122]  C. Supuran,et al.  Structure and inhibition of the CO2-sensing carbonic anhydrase Can2 from the pathogenic fungus Cryptococcus neoformans. , 2008, Journal of molecular biology.

[123]  D. Kelly,et al.  Azole Affinity of Sterol 14α-Demethylase (CYP51) Enzymes from Candida albicans and Homo sapiens , 2012, Antimicrobial Agents and Chemotherapy.

[124]  J. Tkacz,et al.  The fungal cell wall as a drug target. , 1995, Trends in microbiology.

[125]  E. Anaissie,et al.  Factors associated with mortality in transplant patients with invasive aspergillosis. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[126]  E. Borowski Novel approaches in the rational design of antifungal agents of low toxicity. , 2000, Farmaco.

[127]  D. Kontoyiannis,et al.  The epidemiology of Candida glabrata and Candida albicans fungemia in immunocompromised patients with cancer. , 2002, The American journal of medicine.

[128]  T. Walsh,et al.  Activities of Triazole-Echinocandin Combinations against Candida Species in Biofilms and as Planktonic Cells , 2011, Antimicrobial Agents and Chemotherapy.

[129]  M. Cuenca-Estrella,et al.  Importancia clínica de los mecanismos de resistencia de los hongos filamentosos a los antifúngicos , 2002 .

[130]  E. Borowski,et al.  A diffusible analogue of N(3)-(4-methoxyfumaroyl)-L-2,3-diaminopropanoic acid with antifungal activity. , 2001, Microbiology.

[131]  M. Shivaprakash,et al.  Caspofungin first-line therapy for invasive aspergillosis in allogeneic hematopoietic stem cell transplant patients: an European Organisation for Research and Treatment of Cancer study , 2010, Bone Marrow Transplantation.

[132]  C. Supuran Inhibition of carbonic anhydrase from Trypanosoma cruzi for the management of Chagas disease: an underexplored therapeutic opportunity. , 2016, Future medicinal chemistry.

[133]  N. Gow,et al.  Elevated Cell Wall Chitin in Candida albicans Confers Echinocandin Resistance In Vivo , 2011, Antimicrobial Agents and Chemotherapy.